Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN-1: LY3502970 in adults with obesity or overweight with weight-related comorbidities
CTR20232459Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orforglipron in obesity, Overweight, hypertension (HTN), dyslipidemia, obstructive sleep apnea hypopnea syndrome (OSAHS), sponsored by Eli Lilly and Company. Started Oct 2023; status: active.
02
Drugs
orforglipron
03
Conditions
obesityOverweighthypertension (HTN)dyslipidemiaobstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on CTR20232459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232459.